Listen to the article
Uzbekistan has fixed 1 July 2027 as the date by which manufacturers of certain pharmaceuticals and medical devices must operate under a mandatory digital serialisation regime, officials confirmed at a working meeting convened by the Pharmaceutical Products Safety Centre alongside representatives of CRPT Turon LLC and participating domestic producers.
The session reviewed legislative amendments adopted in line with a government decision that launched a special pilot project running from 1 July to 31 December of this year. The pilot covers products falling under Foreign Economic Activity commodity nomenclature codes 3002, 300610, 300660 and 9021909001 — categories that span biological preparations, specific pharmaceutical formulations and a subset of medical equipment.
Five enterprises have so far connected voluntarily to the national information system for digital marking and traceability, known as “Asl belgisi” — three medical device manufacturers and two pharmaceutical producers. Officials described their participation in test procedures as active, and said the phased, planned character of the rollout was proceeding on schedule.
The “Asl belgisi” platform assigns each product unit a unique, non-repeatable Data Matrix barcode at the point of manufacture. That code travels with the item through wholesale and retail distribution channels, with every movement logged in a single electronic database. Citizens can scan the code through a dedicated mobile application to verify a product’s authenticity and quality before use.
Participants at the meeting discussed practical questions arising during the pilot, the sequencing of steps needed to bring additional manufacturers onto the system, and ways to resolve problems that may emerge before the mandatory deadline. Industry representatives’ observations were heard and specific measures were agreed to ensure a successful transition to the compulsory regime by mid-2027.
The serialisation drive is framed by authorities as a central plank of state policy to protect the consumer market from counterfeit and substandard goods, and to bring full traceability to the movement of medicines and medical items from producer to end user.